Original Investigations
Comorbidity and other factors associated with modality selection in incident dialysis patients: The CHOICE study,☆☆,

Presented in part at the 30th Annual Meeting of the American Society of Nephrology, November 2-5, 1997, San Antonio, TX, and the 32nd Annual Meeting of the American Society of Nephrology, November 1-8, 1999, Miami Beach, FL.
https://doi.org/10.1053/ajkd.2002.30552Get rights and content

Abstract

Case-mix factors influence both the selection of dialysis modality and outcomes in end-stage renal disease (ESRD). A detailed characterization of the case-mix differences between peritoneal dialysis (PD) and hemodialysis (HD) patients at the onset of dialysis therapy has not been performed, despite the importance of accounting for baseline differences in future comparisons of outcomes across modality groups. We compared baseline characteristics of 279 PD and 759 HD patients enrolled in the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Cohort Study, a prospective study of incident dialysis patients. Comorbidity was assessed using the Index of Coexistent Diseases (ICED), consisting of a medical record review of 19 medical conditions and an observer-based assessment of 11 physical functions. ICED scores range from 0 to 3, with higher levels reflecting more severe comorbidity. Comorbidity was less severe in PD patients than in HD patients: the proportions of patients with ICED 0-1, ICED 2, and ICED 3 were 52%, 26%, and 22%, respectively, among the PD patients and 30%, 39%, and 31%, respectively, among the HD patients (P < 0.001). After controlling for all other factors, the differences in comorbidity remained significant. As compared with patients with ICED 0-1, the odds of being treated with PD for patients with ICED 2 and ICED 3 were less (odds ratio [OR] and 95% confidence intervals) 0.31 (0.17 to 0.56) and 0.50 (0.28 to 0.90), respectively. The number and severity of comorbid conditions at the onset of ESRD is significantly lower in patients choosing PD, independent of other factors influencing modality selection. The increased survival of PD patients reported in recent studies may simply reflect the self- or physician-directed selection of healthier patients to PD. Adjustment for case-mix differences in patients treated with PD versus HD is essential to the assessment of the independent effect of the dialysis modality on outcomes. © 2002 by the National Kidney Foundation, Inc.

Section snippets

Study design and patient eligibility

We conducted a cross-sectional analysis of baseline data on incident dialysis patients recruited from 81 dialysis units in 19 states of the US participating in the CHOICE Cohort Study. Patients were eligible if they had started chronic outpatient dialysis during the 3 months before enrollment, were 18 years or older, spoke English or Spanish, and gave informed consent. Home HD and hospice patients were excluded.

Patients were recruited from 79 dialysis units associated with Dialysis Clinic, Inc

Recruitment

Approximately two-thirds of eligible patients were enrolled from the participating dialysis units. Eligible patients enrolled were similar to eligible patients not enrolled with regard to gender and age. A total of 1,041 incident dialysis outpatients were enrolled from 81 dialysis centers; 279 PD dialysis (27%) and 762 HD patients (73%). Three HD patients did not have a completed ICED at baseline and were excluded from analyses in this report. Nine hundred and twenty-one patients (89%) were

Discussion

Within the US there is significant variation in PD utilization. Factors responsible for variation are not completely understood, but may include patients' clinical characteristics, medical judgement, physicians' and patients' preferences, and differences in physician and facility reimbursement.24 A detailed characterization of differences in PD versus HD patients in the present study shows the extent by which these patient groups differ at the onset of chronic dialysis therapy.

We observed fewer

Acknowledgements

We thank the patients, staff, and physicians who participated in the CHOICE Study at Dialysis Clinic, Inc, St. Raphael's Hospital and New Haven CAPD. We also acknowledge and thank the CHOICE-DCI Clinical Liaison Committee (Thomas Depner, MD, H. Keith Johnson, MD, K Shashi Kant, MD, Klemens Meyer, MD, Richard Sherman, MD, Edward Schroeder, MD, Pradip Teredesai, MD, John Van Stone, MD, and Philip Zager, MD) and the New Haven CAPD Clinical Liaison Committee (Frederic Finkelstein, MD and Alan

References (34)

  • W McClellan et al.

    Functional status and quality of life: Predictors of early mortality among patients entering treatment for end-stage renal disease

    J Clin Epidemiol

    (1991)
  • GA Kaysen et al.

    Mechanisms of hypoalbuminemia in hemodialysis patients

    Kidney Int

    (1995)
  • LU Mailloux et al.

    The impact of comorbid risk factors at the start of dialysis upon the survival of ESRD patients

    ASAIO J

    (1996)
  • DC Miskulin et al.

    The Index of Coexistent Disease (ICED) is an independent predictor of death in a prospective ESRD cohort

    J Am Soc Nephrol

    (1999)
  • WF Owen et al.

    The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis

    N Engl J Med

    (1993)
  • MV Rocco et al.

    Risk factors for hospital utilization in chronic dialysis patients

    J Am Soc Nephrol

    (1996)
  • US Renal Data System: Excerpts From the USRDS 1999 Annual Data Report

    Am J Kidney Dis

    (1999)
  • Cited by (144)

    • Physical Resilience Phenotype Trajectories in Incident Hemodialysis: Characterization and Mortality Risk Assessment

      2022, Kidney International Reports
      Citation Excerpt :

      Body mass index (in kg/m2) was based on height and weight reported on the Health Care Financing Administration Medical Evidence Report (HCFA Form 2728).17 Kidney disease specific markers selected included the following: (i) type of vascular access, by category: arteriovenous fistula or graft, or central venous catheter or unknown;25 (ii) predialysis initiation nephrology consult timing (early [>12 months], intermediate [4–12 months], late [<4 months], unclassified, or missing)26; (iii) laboratory values for serum albumin (g/dl) obtained from HCFA Form 2728;27 and (iv) estimated glomerular filtration rate, calculated using the 4-variable Modification of Diet in Renal Disease Study equation.28 We modeled comorbidities using the Index of Coexistent Disease (ICED), a validated index of presence and severity of comorbid conditions used extensively in mortality risk prediction in patients with kidney failure.

    • The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care

      2018, Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector’s The Kidney
    View all citing articles on Scopus

    Supported in part by a grant from the Agency for Healthcare Research and Quality (AHRQ) (formerly Agency for Health Care Policy Research [AHCPR] HS08365 to N.R.P.) and a Clinical Research Fellowship from the Alberta Heritage Foundation for Medical Research (to D.C.M.).

    ☆☆

    Address reprint requests to Andrew S. Levey, MD, New England Medical Center, Division of Nephrology, Box 391, Boston, MA 02111. E-mail: [email protected]

    0272-6386/02/3902-0011$35.00/0

    View full text